Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 6/2001

01-12-2001 | Original Article

Phase I clinical and pharmacokinetic trial of irofulven

Authors: James P. Thomas, Rhoda Arzoomanian, Dona Alberti, Chris Feierabend, Kimberly Binger, Kendra D. Tutsch, Thomas Steele, Rebecca Marnocha, Charlotte Smith, Sheri Smith, John MacDonald, George Wilding, Howard Bailey

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2001

Login to get access
Metadata
Title
Phase I clinical and pharmacokinetic trial of irofulven
Authors
James P. Thomas
Rhoda Arzoomanian
Dona Alberti
Chris Feierabend
Kimberly Binger
Kendra D. Tutsch
Thomas Steele
Rebecca Marnocha
Charlotte Smith
Sheri Smith
John MacDonald
George Wilding
Howard Bailey
Publication date
01-12-2001
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 6/2001
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s002800100365

Other articles of this Issue 6/2001

Cancer Chemotherapy and Pharmacology 6/2001 Go to the issue

Original Article

Phase I/II and pharmacologic study of irinotecan and carboplatin for patients with lung cancer

Original Article

Antiangiogenic and antitumor effects of a protein kinase Cβ inhibitor in murine Lewis lung carcinoma and human Calu-6 non-small-cell lung carcinoma xenografts

Original Article

Stereospecific antitumor activity of radicicol oxime derivatives

Original Article

The experimental neuroprotectant leukaemia inhibitory factor (LIF) does not compromise antitumour activity of paclitaxel, cisplatin and carboplatin

Original Article

Gemcitabine activity in cervical cancer cell lines

Original Article

A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits